

- for prevention of death, myocardial infarction, and stroke in high risk patients. *BMJ* 2002;324:71-86.
- Derry S, Loke YK. Risk of gastrointestinal haemorrhage with long term use of aspirin: meta-analysis. *BMJ* 2000;321:1183-7.
 - Chan F, Ching JY, Hung LC, Wong VW, Leung VK, Kung NN, et al. Clopidogrel versus aspirin and esomeprazole to prevent recurrent ulcer bleeding. *N Engl J Med* 2005;352:238-44.
 - Yusuf S, Fox KA, Tognoni G, Mehta SR, Chrolavicius S, Anand S; the Clopidogrel in Unstable Angina to Prevent Recurrent Events (CURE) trial investigators. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. *N Engl J Med* 2001;345:494-502.
 - Sabatine MS, Cannon CP, Gibson CM, Lopez-Sendon JL, Montalescot G, Theroux P, et al. Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation. *N Engl J Med* 2005;352:1179-89.
 - Steinhubl SR, Berger PB, Mann JT, Fry ET, DeLago A, Wilmer C; CREDO Investigators. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. The Clopidogrel for the Reduction of Events During Observation (CREDO) trial. *JAMA* 2002;288:2411-20.
 - Shuchman M. Trading restenosis for thrombosis? New questions about drug-eluting stents. *N Engl J Med* 2006;355:1949-52.
 - Grines CL, Bonow RO, Casey DE, Gardner TJ, Lockhart PB, Moliterno DJ, et al. Prevention of premature discontinuation of dual antiplatelet therapy in patients with coronary artery stents. *Circulation* 2007;115:813-18.
 - Valerin MA, Brennan MT, Noll JL, Napenas JJ, Kent ML, Fox PC, et al. Relationship between aspirin use and postoperative bleeding from dental extractions in a healthy population. *Oral Surg Oral Med Oral Pathol Oral Radiol Endod* 2006;102:326.

Further reading

Stone GW, Aronow HD. Long-term care after percutaneous coronary intervention: focus on the role of antiplatelet therapy. *Mayo Clin Proc* 2006;81:641-52.

Conflict of interest: none declared

Self-test questions

The following statements are either true or false (answers on page 111)

- Patients with drug-eluting stents only need one antiplatelet drug to prevent stent thrombosis.
- Dual antiplatelet therapy has to be continued longer in patients with drug-eluting stents than in patients with bare metal stents.

Medicinal mishap

Bisphosphonates and osteonecrosis of the jaws

Prepared by Alastair Goss, Oral and Maxillofacial Surgeon, and Patricia Backhouse, General Practitioner, Adelaide

Case

An otherwise well 66-year-old woman was referred with pain, swelling and numbness of the left mandible with pus discharging from around a dental implant. Her problems had developed over the previous six months.

The patient had undergone dental reconstruction 15–20 years previously. This involved eight titanium implants in both jaws with extensive crown and bridge work. (This work involved a personal cost of approximately \$25 000 above insurance benefits.)

The woman had been diagnosed with 'borderline osteoporosis'. Her bone mineral density was –2.42 standard deviations below normal (consistent with a diagnosis of osteopenia). She was prescribed 70 mg alendronate weekly but later developed stress fractures. Over three years she took a total dose of 11.2 g.

A clinical diagnosis of bisphosphonate-associated osteonecrosis of the left mandible was made. A CT scan showed extensive

involvement around the infected implant. The right mandible and maxilla were not involved.

Alendronate was ceased and non-surgical treatment commenced with 0.12% chlorhexidine mouth washes, intermittent short courses of cephalosporins for the soft tissue infection, and tramadol or paracetamol with codeine for the pain. This controlled the acute symptoms.

One year after stopping alendronate the symptoms recurred. A repeat CT scan showed extension of the necrosis without bone reformation. The involved implant and soft tissue were curetted under general anaesthesia. The wound healed slowly (see Fig. 1).

Comment

In this case alendronate was commenced before bisphosphonate-associated osteonecrosis of the jaw had been described.¹ Osteonecrosis associated with a previously stable implant was one of the first such presentations in Australia.

Bisphosphonate-associated osteonecrosis of the jaws is now defined as an area of exposed bone in the jaws which persists for more than eight weeks. Other conditions, including osteoradionecrosis and the presence of tumour, need to be excluded. The first described cases were in older, medically compromised patients treated with intravenous infusions